Would you offer trastuzumab-deruxtecan for a metastatic ovarian cancer patient with good performance status whose tumor stains 1+ on IHC for HER2 and who has exhausted all treatment options?

Do you offer trastuzumab deruxtecan to patients who stain 1+ for HER2 on IHC?

• No, they must stain 2+ or 3+ for me to offer it
• Yes, but I would counsel them on a likely lower expected response rate
• Yes, but only if NGS shows ERBB2 amplification
• Other